Literature DB >> 28454327

Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer.

Marcel Matzenauer1, David Vrána1,2,3, Zuzana Vlachová1, Rene Aujesky4, Radek Vrba4, Cestmir Neoral4, Bohuslav Melichar1,2.   

Abstract

Esophageal cancer (EC) consists of tumors with a generally poor prognosis, and treatment options for patients with disease recurrence are extremely limited. Due to this poor patient prognosis, the possible treatment toxicity should be carefully balanced against its potential benefit and patient quality of life. Stereotactic body radiotherapy (SBRT) is a rapidly expanding novel technique combining a short treatment time together with high local efficacy and an acceptable toxicity profile. There are no publications thus far presenting data regarding the usage of SBRT utilizing a conventional linear accelerator in locally recurrent EC patients. In the present study, 2 patients with recurrent EC in the neck lymph nodes were treated by SBRT in the Department of Oncology, University Hospital Olomouc, Czech Republic. The treatment dose was 30 and 40 Gy in 5 daily fractions, with a prescribed dose to 65 and 81% isodose, for each patient respectively, utilizing a volumetric arc therapy technique, a 6-MV photon beam and an Elekta Synergy linear accelerator. The treatment was delivered without any unintentional treatment interruptions and without any treatment-related acute toxicity. The maximum dose in the patients was 45.9 and 49.2 Gy, respectively. The maximum doses for the surrounding major blood vessels were 35.4 and 45.7 Gy, respectively. Maximum doses to the trachea and the esophagus in the first patient were 32.6 and 27.0 Gy. In the second patient, these doses were not clinically significant. SBRT utilizing linear accelerators should be considered in patients with localized recurrent EC, offering the patients the chance for local control with minimal treatment toxicity.

Entities:  

Keywords:  chemotherapy; esophageal cancer; recurrence; stereotactic radiotherapy

Year:  2017        PMID: 28454327      PMCID: PMC5403422          DOI: 10.3892/ol.2017.5605

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  23 in total

1.  Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.

Authors:  Matthew Koshy; Bruce D Greenwald; Petr Hausner; Mark J Krasna; Naomi Horiba; Richard J Battafarano; Whitney Burrows; Mohan Suntharalingam
Journal:  Am J Clin Oncol       Date:  2011-06       Impact factor: 2.339

2.  Radiotherapy management of brain metastases using conventional linear accelerator.

Authors:  Marcel Matzenauer; David Vrana; Zuzana Vlachova; Karel Cwiertka; Ondrej Kalita; Bohuslav Melichar
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2016-09-13       Impact factor: 1.245

3.  Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review.

Authors:  Antonio Pontoriero; Giuseppe Iatì; Dario Aiello; Stefano Pergolizzi
Journal:  Technol Cancer Res Treat       Date:  2015-09-30

4.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

5.  Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors.

Authors:  Alexander Kirichenko; Olivier Gayou; David Parda; Vijay Kudithipudi; Kusum Tom; Akhtar Khan; Peter Abrams; Molly Szramowski; Jose Oliva; Dulabh Monga; Moses Raj; Ngoc Thai
Journal:  HPB (Oxford)       Date:  2015-12-08       Impact factor: 3.647

6.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Authors:  Hansjochen Wilke; Kei Muro; Eric Van Cutsem; Sang-Cheul Oh; György Bodoky; Yasuhiro Shimada; Shuichi Hironaka; Naotoshi Sugimoto; Oleg Lipatov; Tae-You Kim; David Cunningham; Philippe Rougier; Yoshito Komatsu; Jaffer Ajani; Michael Emig; Roberto Carlesi; David Ferry; Kumari Chandrawansa; Jonathan D Schwartz; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2014-09-17       Impact factor: 41.316

7.  Esophageal cancer chemotherapy: recent advances.

Authors:  David H Ilson
Journal:  Gastrointest Cancer Res       Date:  2008-03

8.  Treatment of brain metastases of renal cell cancer with combined hypofractionated stereotactic radiotherapy and whole brain radiotherapy with hippocampal sparing.

Authors:  David Vrána; Hana Študentová; Marcel Matzenauer; Zuzana Vlachová; Karel Cwiertka; David Gremlica; Ondřej Kalita
Journal:  Oncol Lett       Date:  2016-04-15       Impact factor: 2.967

9.  Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.

Authors:  Jens Hoeppner; Katja Zirlik; Thomas Brunner; Peter Bronsert; Birte Kulemann; Olivia Sick; Goran Marjanovic; Ulrich Theodor Hopt; Frank Makowiec
Journal:  J Surg Oncol       Date:  2013-11-26       Impact factor: 3.454

10.  Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy.

Authors:  Young Suk Kim; Chang Geol Lee; Kyung Hwan Kim; Taehyung Kim; Joohwan Lee; Yona Cho; Woong Sub Koom
Journal:  Radiat Oncol J       Date:  2012-12-31
View more
  3 in total

Review 1.  Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy.

Authors:  Xiu-Yong Liao; Chao-Yuan Liu; Jian-Feng He; Li-Shu Wang; Tao Zhang
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967

Review 2.  ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Authors:  David Vrana; Viktor Hlavac; Veronika Brynychova; Radka Vaclavikova; Cestmir Neoral; Jiri Vrba; Rene Aujesky; Marcel Matzenauer; Bohuslav Melichar; Pavel Soucek
Journal:  Int J Mol Sci       Date:  2018-03-15       Impact factor: 5.923

3.  Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma.

Authors:  Steven N Seyedin; Margaret K Gannon; Kristin A Plichta; Laith Abushahin; Daniel J Berg; Evgeny V Arshava; Kalpaj R Parekh; John C Keech; Joseph M Caster; James W Welsh; Bryan G Allen
Journal:  Front Oncol       Date:  2020-07-31       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.